Healthcare professionals predict further Brexit delay

15 August 2019

What do healthcare professionals (HCPs) in the UK, Europe and the USA think will happen next in the Brexit saga?

The most common answer among UK and US HCPs, according to a GlobalData survey, is that there will be further Brexit delays once the current deadline of October 31 is reached. However, 43% of European Union (EU) respondents now expect a no deal Brexit.

Urte Jakimaviciute, senior director of market research at GlobalData, said: “Theresa May’s withdrawal agreement has already been rejected three times by the UK parliament. With the EU and the UK making no further progress to address the Irish border issue, it is unlikely that the agreement will be sealed.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK